Lanbao

Zhejiang Lanbao Pharmaceutical, also known as Lambor Pharmaceutical, is a Chinese pharmaceutical company specializing in the development and large-scale manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. The company's core portfolio includes cardiovascular treatments, particularly statins, as well as central nervous system drugs and anti-infectives. Since its acquisition by Zhejiang Jingxin Pharmaceutical in 2015, Lanbao has operated as a key subsidiary, leveraging its GMP-certified facilities to supply global markets. The company is recognized for its high-quality production of chemical drugs like Simvastatin and Sertraline. Lanbao maintains a strong focus on international quality standards, exporting products to Europe, North America, and Southeast Asia. Its manufacturing capabilities include large-scale chemical synthesis and advanced formulation development.